Background
Methods
Patients
Statistical analysis
Results
Patients and tumor characteristics
Category | N (%) |
---|---|
Age at diagnosis(years) | |
≤ 60 | 128(45.1%) |
> 60 | 156(54.9%) |
mean | 60.5 Years |
median | 63 Years |
Gender | |
Female | 102(35.9%) |
Male | 182(64.1%) |
Race | |
White | 228(80.3%) |
Black | 25(8.8%) |
Other | 31(10.9%) |
Year of diagnosis | |
2010–2012 | 111(39.1%) |
2013–2014 | 86(30.3%) |
2015–2016 | 87(30.6%) |
Metastatic sites at diagnosis | |
Bone | |
Yes | 121(42.6%) |
No | 163(57.4%) |
Brain | |
Yes | 26(9.2%) |
No | 258(90.8%) |
Liver | |
Yes | 86(30.3%) |
No | 198(69.7) |
Lung | |
Yes | 171(60.2%) |
No | 113(39.8%) |
Number of metastatic sites | |
1 | 188(66.2%) |
≥ 2 | 96(33.8%) |
Grade | |
I + II | 6(2.1%) |
III | 52(18.3%) |
IV | 50(17.6%) |
Unknown | 176(62.0%) |
Size(cm) | |
≤ 10 | 110(38.7%) |
> 10 | 44(15.5%) |
Unknown | 130(45.8%) |
Treatment | |
Chemotherapy | |
Yes | 145(51.1%) |
No | 139(48.9%) |
RT | |
Yes | 66(23.2%) |
No | 218(76.8%) |
ST | |
Yes | 83(29.2%) |
No | 201(70.8%) |
Dead | |
Yes | 253(89.1%) |
No | 31(10.9%) |
1-year OS rate | 20.8% |
3-year OS rate | 3.8% |
1-year CSS rate | 22.0% |
3-year CSS rate | 5.2% |
Variable | OS | CSS | ||
---|---|---|---|---|
Estimate ± SE | 95%CI | Estimate ± SE | 95%CI | |
Age at diagnosis (years) | ||||
≤ 60 | 5.0 ± 0.9 | 3.323–6.677 | 5.0 ± 0.9 | 3.228–6.772 |
> 60 | 2.0 ± 0.4 | 1.168–2.832 | 2.0 ± 0.5 | 1.005–2.995 |
Gender | ||||
Female | 4.0 ± 0.7 | 2.575–5.425 | 4.0 ± 1.0 | 2.100–5.900 |
Male | 3.0 ± 0.6 | 1.795–4.205 | 3.0 ± 0.6 | 1.845–4.155 |
Race | ||||
White | 3.0 ± 0.5 | 2.063–3.937 | 3.0 ± 0.5 | 1.972–4.028 |
Black | 4.0 ± 1.7 | 0.757–7.243 | 4.0 ± 1.4 | 1.309–6.691 |
Other | 6.0 ± 4.2 | 0.000–14.305 | 6.0 ± 2.6 | 0.842–11.158 |
Year of diagnosis | ||||
2010–2012 | 4.0 ± 1.0 | 2.068–5.932 | 3.0 ± 0.9 | 1.280–4.720 |
2013–2014 | 4.0 ± 0.8 | 2.403–5.597 | 3.0 ± 0.9 | 1.272–4.728 |
2015–2016 | 3.0 ± 0.6 | 1.844–4.156 | 3.0 ± 1.0 | 1.124–4.876 |
Grade | ||||
I + II | N/A | N/A | 3.0 ± 0.6 | 1.863–4.137 |
III | 4.0 ± 1.0 | 2.137–5.863 | 4.0 ± 1.5 | 0.986–7.014 |
IV | 4.0 ± 0.7 | 2.534–5.466 | 4.0 ± 0.7 | 2.588–5.412 |
NO. of metastatic sites | ||||
1 | 3.0 ± 0.6 | 1.789–4.211 | 4.0 ± 0.9 | 2.162–5.838 |
≥ 2 | 3.0 ± 0.7 | 1.589–4.411 | 3.0 ± 0.7 | 1.629–4.371 |
Size (cm) | ||||
≤ 10 | 6.0 ± 1.1 | 3.887–8.113 | 9.0 ± 1.9 | 5.337–12.663 |
> 10 | 2.0 ± 0.7 | 0.701–3.299 | 3.0 ± 0.6 | 1.840–4.160 |
Treatment | ||||
Chemotherapy | ||||
Yes | 8.0 ± 1.0 | 6.083–9.917 | 8.0 ± 1.3 | 5.444–10.556 |
No | 1.0 ± 0.2 | 0.692–1.308 | 1.0 ± 0.2 | 0.636–1.364 |
RT | ||||
Yes | 7.0 ± 1.6 | 3.875–10.125 | 6.0 ± 1.6 | 2.870–9.130 |
No | 3.0 ± 0.4 | 2.202–3.798 | 3.0 ± 0.4 | 2.200–3.800 |
ST | ||||
Yes | 3.0 ± 0.5 | 2.022–3.978 | 3.0 ± 0.6 | 1.876–4.124 |
No | 3.0 ± 0.7 | 1.710–4.290 | 3.0 ± 0.7 | 1.621–4.379 |
Overall | 3.0 ± 0.5 | 2.078–3.922 | 3.0 ± 0.5 | 1.979–4.021 |
Univariate analysis of variables associated with OS or CSS in MAS patients
Category | OS (log-rank P-value) | CSS (log-rank P-value) |
---|---|---|
Age at diagnosis(years) | 0.003 | 0.036 |
Gender | 0.567 | 0.139 |
Race | 0.594 | 0.348 |
Year of diagnosis | 0.770 | 0.955 |
Grade (III vs. IV) | 0.187 | 0.024 |
Number of metastatic sites | 0.287 | 0.113 |
Size (≤10 cm vs. > 10 cm) | < 0.001 | < 0.001 |
Treatment | ||
Chemotherapy | < 0.001 | < 0.001 |
RT | 0.009 | 0.077 |
ST | 0.192 | 0.251 |
Multivariate analysis of independent predictors of OS or CSS in MAS patients
Category | OS | CSS | ||
---|---|---|---|---|
HR (95%CI) | P-value | HR (95%CI) | p-value | |
Age at diagnosis(years) | 1.074(0.824–1.400) | 0.597 | 1.160(0.854–1.575) | 0.342 |
Grade (III vs. IV) | – | – | 2.052(1.220–3.452) | 0.007 |
Size (≤10 cm vs. > 10 cm) | 1.956(1.345–2.843) | < 0.001 | 2.316(1.495–3.586) | < 0.001 |
Chemotherapy | 2.956(2.233–3.913) | < 0.001 | 3.308(2.379–4.600) | < 0.001 |
RT | 1.580(1.162–2.149) | 0.004 | – | – |